Enhanced Mdm2 activity inhibits pRB function via ubiquitin-dependent degradation

被引:152
作者
Uchida, CH
Miwa, SC
Kitagawa, K
Hattori, T
Isobe, T
Otani, S
Kamijo, T
Ookawa, K
Yasuda, H
Kitagawa, M
Oda, T
Sugimura, H
机构
[1] Hamamatsu Univ Sch Med, Dept Biochem 1, Shizuoka 4313192, Japan
[2] Hamamatsu Univ Sch Med, Dept Internal Med 2, Shizuoka 4313192, Japan
[3] Hamamatsu Univ Sch Med, Dept Pathol 1, Shizuoka 4313192, Japan
[4] Shinshu Univ, Sch Med, Dept Pediat, Nagano, Japan
[5] Hirosaki Univ, Sch Med, Dept Biochem 2, Hirosaki, Aomori 036, Japan
[6] Nippon Flour Mills Co Ltd, Cent Lab, Div Biosci, Kanagawa, Japan
关键词
Mdm2; p53; RB protein; tumor suppressor; ubiquitin ligase;
D O I
10.1038/sj.emboj.7600486
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Retinoblastoma gene product ( pRB) plays critical roles in regulation of the cell cycle and tumor suppression. It is known that downregulation of pRB can stimulate carcinogenesis via abrogation of the pRB pathway, although the mechanism has not been elucidated. In this study, we found that Mdm2, a ubiquitin ligase for p53, promoted ubiquitin- dependent degradation of pRB. pRB was efficiently ubiquitinated by wild- type Mdm2 in vivo as well as in vitro, but other RB family proteins were not. Mutant Mdm2 with a substitution in the RING finger domain showed dominant- negative stabilization of pRB. Both knockout and knockdown of Mdm2 caused accumulation of pRB. Moreover, Mdm2 inhibited pRB- mediated flat formation of Saos- 2 cells. Downregulation of pRB expression was correlated with a high level of expression of Mdm2 in human lung cancers. These results suggest that Mdm2 regulates function of pRB via ubiquitin- dependent degradation of pRB.
引用
收藏
页码:160 / 169
页数:10
相关论文
共 40 条
[21]   Overexpression of p16ink4a as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri [J].
Klaes, R ;
Friedrich, T ;
Spitkovsky, D ;
Ridder, R ;
Rudy, W ;
Petry, U ;
Dallenbach-Hellweg, G ;
Schmidt, D ;
Doeberitz, MV .
INTERNATIONAL JOURNAL OF CANCER, 2001, 92 (02) :276-284
[22]   Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase [J].
Koepp, DM ;
Schaefer, LK ;
Ye, X ;
Keyomarsi, K ;
Chu, C ;
Harper, JW ;
Elledge, SJ .
SCIENCE, 2001, 294 (5540) :173-177
[23]   Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation [J].
Leng, RP ;
Lin, YP ;
Ma, WL ;
Wu, H ;
Lemmers, B ;
Chung, S ;
Parant, JM ;
Lozano, G ;
Hakem, R ;
Benchimol, S .
CELL, 2003, 112 (06) :779-791
[24]   The p53-Mdm2 module and the ubiquitin system [J].
Michael, D ;
Oren, M .
SEMINARS IN CANCER BIOLOGY, 2003, 13 (01) :49-58
[25]   Targeted disruption of Skp2 results in accumulation of cyclin E and p27Kip1, polyploidy and centrosome overduplication [J].
Nakayama, K ;
Nagahama, H ;
Minamishima, YA ;
Matsumoto, M ;
Nakamichi, I ;
Kitagawa, K ;
Shirane, M ;
Tsunematsu, R ;
Tsukiyama, T ;
Ishida, N ;
Kitagawa, M ;
Nakayama, K ;
Hatakeyama, S .
EMBO JOURNAL, 2000, 19 (09) :2069-2081
[26]   AMPLIFICATION OF A GENE ENCODING A P53-ASSOCIATED PROTEIN IN HUMAN SARCOMAS [J].
OLINER, JD ;
KINZLER, KW ;
MELTZER, PS ;
GEORGE, DL ;
VOGELSTEIN, B .
NATURE, 1992, 358 (6381) :80-83
[27]   Differentiation induced by RB expression and apoptosis induced by p53 expression in an osteosarcoma cell line [J].
Ookawa, K ;
Tsuchida, S ;
Adachi, J ;
Yokota, J .
ONCOGENE, 1997, 14 (12) :1389-1396
[28]   Alterations in expression of E2F-1 and E2F-responsive genes by RB, p53 and p21Sid1/WAF1/Cip1 expression [J].
Ookawa, K ;
Tsuchida, S ;
Kohno, T ;
Yokota, J .
FEBS LETTERS, 2001, 500 (1-2) :25-30
[29]   The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53 [J].
Pomerantz, J ;
Schreiber-Agus, N ;
Liegeois, NJ ;
Silverman, A ;
Alland, L ;
Chin, L ;
Potes, J ;
Chen, K ;
Orlow, I ;
Lee, HW ;
Cordon-Cardo, C ;
DePinho, RA .
CELL, 1998, 92 (06) :713-723
[30]   IDENTIFICATION OF A GROWTH SUPPRESSION DOMAIN WITHIN THE RETINOBLASTOMA GENE-PRODUCT [J].
QIN, XQ ;
CHITTENDEN, T ;
LIVINGSTON, DM ;
KAELIN, WG .
GENES & DEVELOPMENT, 1992, 6 (06) :953-964